Hoth Therapeutics (HOTH) said Wednesday its therapeutic candidate, HT-001, showed "promising" results in a patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab.
The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors, the company said.
"After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks," it said.
The data will be presented at the upcoming American Academy of Dermatology annual meeting, Hoth said. A phase 2A trial of HT-001 in a broader patient population is being conducted.
The shares were over 7% lower in recent trading.
Price: 1.15, Change: -0.10, Percent Change: -7.66
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。